Ginkgo Bioworks/$DNA

13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX

About Ginkgo Bioworks

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Ticker

$DNA
Sector

Primary listing

NYSE

Industry

Chemicals

Employees

834

ISIN

US37611X2099

Ginkgo Bioworks Metrics

BasicAdvanced
$502M
-
-$8.92
1.29
-

Bulls say / Bears say

Ginkgo Bioworks' strategic partnership with Google Cloud aims to develop large language models for genomics and synthetic biology, potentially accelerating innovation and discovery in these fields. (benzinga.com)
The collaboration with Pfizer to advance novel RNA molecules includes potential milestone payments and royalties up to $331 million, providing a significant financial boost and validating Ginkgo's platform. (investing.com)
In Q1 2025, Ginkgo reported a 27% increase in total revenue to $48 million, driven by a $7 million rise in cell engineering revenue, indicating strong growth in its core business segment. (finviz.com)
Ginkgo's Q4 2024 net loss was $107.5 million, exceeding analyst estimates of $80.1 million, raising concerns about its path to profitability. (tradingview.com)
The company forecasted 2025 revenue between $160 million and $180 million, below analyst expectations of $189 million, suggesting potential challenges in meeting growth targets. (tradingview.com)
Ginkgo's stock has declined 82.4% over the past 12 months, reflecting investor skepticism and potential challenges in the biotech sector. (tradingview.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DNA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs